Eric Schmidt Analyst Performance

Eric Schmidt is a stock analyst at Cantor Fitzgerald, covering 32 publicly traded companies across a range of sectors. Over the past year, Eric Schmidt has issued 13 stock ratings, including buy and hold recommendations. While full access to Eric Schmidt's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eric Schmidt's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Analyst Rating

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

114 Last 10 Years

Buy Recommendations

83.33% 95 Buy Ratings

Companies Covered

32 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	83.3%	95 ratings
Hold	16.7%	19 ratings
Sell	0.0%	0 ratings

Out of 114 total stock ratings issued by Eric Schmidt at Cantor Fitzgerald, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  EXEL

  Mar 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  RGLS

  Jun 2016

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	90.6% of companies on NASDAQ	29 companies
NYSE	9.4% of companies on NYSE	3 companies

Eric Schmidt, an analyst at Cantor Fitzgerald, currently covers 32 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 27 companies	84.4%
	Miscellaneous 5 companies	15.6%

Eric Schmidt of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 19 companies	59.4%
PHARMACEUTICAL PREPARATIONS 5 companies	15.6%
Miscellaneous 4 companies	12.5%
MED - DRUGS 3 companies	9.4%
HOLDING & OTHER INVESTMENT OFFICES 1 company	3.1%

Eric Schmidt's Ratings History at Cantor Fitzgerald

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
SMMT Summit Therapeutics	9/8/2025	Reiterated Rating	$22.00		Overweight	$0.00 00.00% ROI
LEGN Legend Biotech	8/27/2025	Reiterated Rating	$35.08	$66.00	Overweight	$0.00 00.00% ROI
SRRK Scholar Rock	7/17/2025	Initiated Coverage	$41.15		Overweight	$0.00 00.00% ROI
RNA Avidity Biosciences	6/27/2025	Reiterated Rating	$29.83	$96.00	Overweight	$0.00 00.00% ROI
IMTX Immatics	4/1/2025	Reiterated Rating	$4.23		Overweight	$0.00 00.00% ROI
GLYC GlycoMimetics	3/21/2025	Initiated Coverage	$0.27		Overweight	$0.00 00.00% ROI
SMMT Summit Therapeutics	3/21/2025	Initiated Coverage	$19.44		Overweight	$0.00 00.00% ROI
ALMS Alumis	3/20/2025	Reiterated Rating	$4.33		Overweight	$0.00 00.00% ROI
ADCT ADC Therapeutics	3/7/2025	Reiterated Rating	$1.84		Overweight	$0.00 00.00% ROI
PRTA Prothena	2/21/2025	Reiterated Rating	$15.78		Overweight	$0.00 00.00% ROI
CRSP CRISPR Therapeutics	2/19/2025	Reiterated Rating	$53.38		Neutral	$0.00 00.00% ROI
CDTX Cidara Therapeutics	1/27/2025	Reiterated Rating	$19.51		Overweight	$0.00 00.00% ROI
INCY Incyte	1/10/2025	Reiterated Rating	$70.17		Neutral	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.